Infectious Disease Treatments Market Research Report – Forecast Till 2030

Infectious Disease Treatments Market Research Report: Information By Type (Viral Diseases, Bacterial Diseases) Treatment (Antibacterial, Antifungal Drugs, Antiviral Drugs) End Users (Hospitals & Clinics, Retail Pharmacies) - Forecast till 2030

ID: MRFR/Pharma/1095-HCR | January 2023 | Region: Global | 90 Pages         

Infectious Disease Treatments Market Speak to Analyst Request a Free Sample

Infectious Disease Treatments Market Scenario 


The infectious disease treatments market is projected to reach USD 25,401.96 Million by 2030 at 6.7% CAGR during the forecast period 2022-2030.Infectious diseases can be caused by a variety of organisms that are inclusive of bacteria, viruses, fungi, and parasites. Some infectious diseases are contagious and can be passed from person to person. Few of these infectious diseases are transmitted by the bites of insects or animals while few are also acquired by ingestion of contaminated water or food. Some of the common examples of infectious diseases are acquired immunodeficiency syndrome (AIDS), hepatitis B, tuberculosis (TB), and others. Increasing prevalence of the infectious diseases like TB, AIDS, and others across the globe is one of the major drivers for the growth of the infectious disease treatments market during the forecast period. In 2016, according to the Centers for Disease Control and Prevention, TB affected one-third of the world’s population. Moreover, it was estimated that 10.4 million people around the world were detected with TB disease and the disease led to 1.7 million, people globally. Additionally, according to the World Health Organisation, in 2016, 36.7 million people lived with HIV/AIDS and the disease caused 1.0 million deaths, globally. Besides this, increasing healthcare expenditures, growing awareness of the patients will further boost the infectious disease treatments market growth. However, low adoption of the treatment and low per capita healthcare expenditure in the developing economies may restrain the infectious disease treatments market growth during the forecast period. 


Segmentation


The infectious disease treatments market is segmented on the basis of type, treatment, and end users.


On the basis of the type, the infectious disease treatments market is segmented into viral diseases, bacterial diseases, and others. The viral diseases segment is sub-segmented into acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C, and others. The bacterial diseases segment is sub-segmented into tuberculosis (TB), bacterial meningitis, and others.


On the basis of the treatment, the infectious disease treatments market is segmented into antibacterial drugs, antifungal drugs, antiviral drugs, anti-parasitic drugs, and others. The antibacterial drugs segment is sub-segmented into beta-lactams, quinolones, sulfonamides, tetracyclines, and others. The antifungal drugs segment is sub-segmented into azoles, pyrimidines, echinodians, polyenes, and others.


On the basis of application, the infectious disease treatments market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.


On the basis of the end users, the infectious disease treatments market is segmented into hospitals & clinics, research organization, retail pharmacies, and others. 


Regional Analysis


The Americas dominate the infectious disease treatments market. A well-developed healthcare sector and huge patient population for infectious diseases followed by increasing healthcare expenditure and changing lifestyle drive the infectious disease treatments market growth in the Americas. Moreover, the presence of global players like Merck & Co., Inc., Pfizer Inc., and others within the region fuels the infectious disease treatments market growth during the forecast period. 


Europe is the second largest infectious disease treatments market. High healthcare expenditures, government support for research & development, and huge patient population drives the European market. Moreover, the presence of the developed economies within the region like Germany, the U.K, and France fuels the infectious disease treatments market growth during the forecast period. 


Asia Pacific is the fastest growing region in the global infectious disease treatments market due to the presence of a huge patient population and continuously developing economies like India and China which have a growing healthcare industry. Additionally, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax in India boosts the regional market growth. 


On the other hand, the Middle East & Africa holds the least share in the global infectious disease treatments market due to the presence of poor economies in the African region. Moreover, the low per capita income and stringent government policies restrain the infectious disease treatments market growth within the African region. A majority of the market in the Middle East & Africa is held by the Middle East due to huge healthcare expenditures and presence of developed economies like Kuwait, Saudi Arabia, Dubai, and Qatar.


Key players for infectious disease treatments market


Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Novartis AG (Switzerland), Sanofi (France), Mylan N.V. (U.S.), and others are some of the key players for the infectious disease treatments market.


Intended Audience




  • Pharmaceutical Companies




  • Biotechnological Institutes




  • Research and Development (R&D) Companies




  • Medical Research Laboratories




  • Market Research and Consulting Service Providers 





Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 25,401.96 Million
  CAGR   6.7% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, and End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Novartis AG (Switzerland), Sanofi (France), Mylan N.V. (U.S.), and others
  Key Market Opportunities

  • Increasing healthcare expenditures
  • Growing awareness of the patients
  •   Key Market Drivers   Increasing prevalence of the infectious diseases


    Speak to Analyst Ask for Customization